Metagenomi (NASDAQ:MGX – Get Free Report) and Burning Rock Biotech (NASDAQ:BNR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Profitability
This table compares Metagenomi and Burning Rock Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Metagenomi | -384.61% | -63.65% | -44.52% |
| Burning Rock Biotech | -13.60% | -12.98% | -8.59% |
Earnings & Valuation
This table compares Metagenomi and Burning Rock Biotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Metagenomi | $25.21 million | 1.16 | -$87.87 million | ($2.49) | -0.31 |
| Burning Rock Biotech | $77.16 million | 1.85 | -$7.92 million | ($0.87) | -15.61 |
Burning Rock Biotech has higher revenue and earnings than Metagenomi. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
30.0% of Burning Rock Biotech shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for Metagenomi and Burning Rock Biotech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Metagenomi | 1 | 0 | 2 | 0 | 2.33 |
| Burning Rock Biotech | 1 | 0 | 0 | 0 | 1.00 |
Metagenomi currently has a consensus target price of $6.00, suggesting a potential upside of 678.21%. Given Metagenomi’s stronger consensus rating and higher possible upside, research analysts plainly believe Metagenomi is more favorable than Burning Rock Biotech.
Risk & Volatility
Metagenomi has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Summary
Burning Rock Biotech beats Metagenomi on 10 of the 14 factors compared between the two stocks.
About Metagenomi
Metagenomi, Inc. is a biotechnology company focused on developing genetic medicines using genome-editing technologies. The company uses metagenomics—the study of genetic material recovered from environmental microorganisms—to discover and characterize naturally occurring CRISPR systems and other programmable enzymes that may offer advantages over conventional gene-editing tools. Metagenomi’s technology platform is designed to support the development of therapies for genetic diseases by enabling targeted DNA editing, including gene insertion, deletion and correction.
About Burning Rock Biotech
Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS) tests designed to help detect cancer, guide treatment decisions and monitor patients during therapy. Its offerings include tissue- and blood-based genomic testing for cancer patients, as well as tests intended to support therapy selection, treatment monitoring and the identification of biomarkers relevant to targeted medicines and immunotherapies.
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.
